NASDAQ:COGT 10 November 2025

Cogent Biosciences (COGT) stock slips as insider sales follow bezuclastinib FDA filing

Shares of Cogent Biosciences slid on Wednesday, paring losses from earlier in the session, after the biotech disclosed a key regulatory filing while investors digested a cluster of insider stock sales. The stock was down 2.5% at $36.19, after touching a low of $34.33.

31 December 2025

Biotechnology·NASDAQ:COGT·Stock Market

Why Cogent Biosciences stock is down today after its FDA filing for bezuclastinib

Shares of Cogent Biosciences, Inc. fell 2.7% to $36.88 on Tuesday after the biotech said it submitted a New Drug Application to the U.S. Food and Drug Administration for its drug candidate bezuclastinib in nonadvanced systemic mastocytosis. Yahoo Finance

30 December 2025

NASDAQ:COGT·Pharmaceuticals·Stock Market

Cogent Biosciences (COGT) soars ~115% after PEAK Phase 3 shows 16.5‑month PFS in GIST; NDA targeted for 1H 2026 (Nov. 10, 2025)

Cogent Biosciences announced positive top‑line results from its Phase 3 PEAK trial testing bezuclastinib plus sunitinib in second‑line gastrointestinal stromal tumor, sending the stock sharply higher in Monday trading. The combination delivered a median progression‑free survival of 16.5 months vs. 9.2 months for sunitinib alone and a 46% objective response rate vs. 26% on sunitinib monotherapy. GlobeNewswire

10 November 2025

Biotechnology·NASDAQ:COGT·Pharmaceutical News·Stock Market